Introduction
Bone is a heterogeneous composite material consisting, in decreasing order, of a mineral phase, hydroxyapatite (Ca 10 (PO 4 ) 6 (OH) 2 ) (analogous to geologic 'hydroxyapatite'), 1 an organic phase (B90% type I collagen, B5% noncollagenous proteins (NCPs), B2% lipids by weight) 2 and water. Proteins in the extracellular matrix of bone can also be divided as follows: (a) structural proteins (collagen and fibronectin) and (b) proteins with specialized functions, such as those that (i) regulate collagen fibril diameter, (ii) serve as signaling molecules, (iii) serve as growth factors, (iv) serve as enzymes and (v) have other functions. The relative amount of each of these constituents present in a given bone varies with age, 3 site, 4 gender, 5 ethnicity 6 and health status. 7 The amount, proper arrangement and characteristics of each of these components (quantity and quality) define the properties of bone. The tendency of bones to fracture depends on the quantity of mineralized tissue present (size and density) often measured by clinicians as bone mineral density or BMD 8 and several other factors, grouped together as 'bone quality'. 8, 9 'Bone quality' factors include composition (weight percent of each component), mineralization (organization of the mineral and its crystallite size and perfection), collagen content and collagen crosslinks, morphology, 10 microarchitecture 11 and the presence of microcracks. 12 Each of these factors varies with health, disease and drug therapies. Their distribution in the heterogeneous tissue also varies with these perturbations. The focus of this review will be on the composition of bone and its site-specific variation. Materials present, their characteristics and their distribution will be discussed here. Readers are referred to the references above for more information on morphology, microarchitecture and the presence of microcracks, which will not be discussed.
Bone Mineral
Hydroxyapatite is the principal component of the mineral phase of bone. This was demonstrated more than 60 years ago using X-ray diffraction, now viewed as the 'gold standard' for such determinations. 1 The quantity of mineral present in bone can be determined by a variety of techniques 13 including gravimetric analyses (ash weight determination), analysis of calcium and phosphate contents, spectroscopic and densitometric analyses including bone mineral density distribution (BMDD), bone mineral density (BMD) and micro-computed tomography (micro-CT). Such methods show that the mineral content of bone ranges from B30%/dry weight (in the skate or ray appendicular skeletal element, the propterygium) to 98%/dry weight in the stapes of the human ear. Most bones have B60-70% mineral/dry weight, depending upon site, species and stage of development ( Figure 1) . 13, 14 Variation in the distribution of mineral and its properties in bone can be illustrated by a variety of imaging techniques, discussed here, including BMDD, Raman and infrared spectroscopic imaging. It can also be determined by microprobe or synchrotron radiation-induced micro-X-ray fluorescence elemental analysis and mapping 15 including trace elements such as strontium, aluminum, zinc or lead. In contrast, backscattered electron imaging in the scanning electron microscope is highly sensitive to the average atomic number of the bone material that is dominated by calcium. This technique is not a tool to identify specific elements in bone. Quantitative backscattered electron imaging is used for mapping the calcium concentrations and for the determination of bone mineralization density distribution (frequency distribution of Ca concentrations within the bone sample, BMDD; Figure 2 ). 16 Parameters obtained from BMDD include the average and mode Ca content and the full-width at half-maximum of the BMDD peak, which is a measure of the heterogeneity of mineralization. Deviations from normal calcium distributions have been reported to date in: osteomalacia, 17 osteoporosis 18 and idiopathic osteoporosis 19 (peak shifted to the left of normal), classical and new forms of osteogenesis imperfecta 16, 20 (peak shifted to the right of normal) and treatment with some but not all bisphosphonates examined by this technique. 18, 21, 22 Variation in phosphate distribution is visualized by both Fourier transform infrared microscopic imaging (FTIRI) 23 and Raman microscopy and imaging (Raman). 24, 25 These types of vibrational spectroscopic imaging describe the distribution of any elemental pair or larger moiety that vibrates when excited by incident light. Relevant vibrations for bone are those in phosphate, protein and lipid groups. The precise location of the vibrations, often given in wave numbers or reciprocal wavelength, reflects the molecular environment in which the vibrating ions are found. In addition, as with BMDD, the line width at halfmaximum of any of the broadened peaks indicates the heterogeneity (number of pixels with different values in the section analyzed) for that particular vibration. The spatial resolution of the FTIRI experiment, unless synchrotron radiation is used, is B7 mm. Raman spectroscopy, in contrast, has a spatial resolution of B1 mm. Raman spectral data is not affected by the presence of water, making the analysis of non-dehydrated samples, not possible for FTIRI, yet possible using Raman. Vibrations that are strong in the infrared spectra are weak in Raman spectra, and vice versa. These two are complimentary techniques, providing information on both the mineral phosphate and the organic matrix distribution in tissues ( . The data from these images can be presented as 'chemical photographs' (as in Figures 3 and 5 ) or as numerical averages ( Figure 6 ). Data in Figure 6 compares the composition of cancellous bone in patients treated with bisphosphonate followed by 1 year of teriparatide (PTH) treatment, as determined by Raman spectroscopy. The lower half of Figure 6 shows baseline values as determined by FTIRI in an on-going study of female patients with and without fragility fractures. The mean heterogeneity for each of these parameters is also shown. An important observation is that the fracture cases had reduced heterogeneities relative to unfractured controls. We believe (discussed later) that this loss of compositional heterogeneity may allow microcrack propagation resulting in a weakened, more brittle tissue as the microcracks spread. Whether this change in heterogeneity is due to oversuppression or other mechanisms is yet to be determined.
Using FTIRI spectroscopy, biopsies from patients with lowenergy (fragility) fractures were found to exhibit differences in their mineral composition, relative to the same tissue in fracturefree controls of similar age and sex. Using these FTIRI analyses of 54 iliac crest biopsies from patients ranging in age from 30 to 84 years, with and without fragility fractures, 26 models were constructed to determine which FTIRI parameters were associated with fracture. The mineral parameters significantly associated with fracture in the constructed model were high cortical mineral/matrix ratio (increased fracture risk) and high cancellous crystallinity (increased fracture risk). Carbonate-tophosphate ratio was increased in both areas, however, not significantly. Raman analysis performed on femoral cancellous 27 These compositional changes and the loss of heterogeneity reflect the persistence of older more mature bone (increased mineral/ matrix ratio and carbonate/phosphate ratio and a lower acid phosphate substitution) along with the absence of new bone formation.
Changes in mineral composition also occur in other bone diseases associated with increased fracture risk in addition to osteoporosis. In most types of OI (or brittle bone disease), as in osteoporosis, the mineral content (mineral/matrix ratio) is increased. 28 In osteoporosis, this increase is attributable to the lack of osteoid associated with increased remodeling and decreased bone formation, whereas in OI there is a lesser amount of collagen because OI patients make an improper collagen matrix. 28 In osteomalacia, the mineral/matrix ratio is unchanged when mineralized tissue alone is examined. 29 Crystallinity (measured based on different vibrations in FTIRI and Raman 30 ) generally shows parallel trends. These trends, reflecting the changes in mineral properties in different diseases, are summarized in Table 1 along with other compositional parameters measured by FTIRI and Raman. Carbonate/ phosphate ratio, based on the same vibrations in both techniques varies similarly. The extent of acid phosphate substitution 31 varies inversely with crystallinity. For example, in chronic kidney disease, abnormalities in phosphate transport and clearance lead to osteoporosis and increased crystallinity when bone turnover is high, with no significant changes occurring when bone turnover is low. 32 
Bone Matrix
Protein composition of bone was classically determined following demineralization of the tissue and isolation and characterization of the component proteins. Collagen, predominantly type I, accounted for the majority of the matrix, but other proteins, the so-called NCPs, accounted for B5% of the total bone weight. The major components of the NCPs were identified as belonging to the SIBLING (small integrin-binding N-glycosylated), SLRP (small leucine-rich proteoglycans), GLA protein (g-carboxyglutamic acid protein) and CCN protein (small secreted cysteine-rich protein) families. Today, using proteomics and gene expression profiling, it is known that there are thousands of proteins in the bone matrix, some of which (based on whole-genome analysis) have been associated with changes in BMD, but most are yet to be identified and their functions determined. Major structural proteins and NCPs will be reviewed here.
Structural proteins. Collagen. The most abundant protein in the bone matrix is type I collagen, a unique triple helical molecule consisting of two identical amino-acid chains and one that is different. The collagen molecules that consist of repeating glycine-X-Y residues are often hydroxylated and glycosylated. This gives rise to some of collagen's unique crosslinking ability, in turn, making the collagen lattice ideal for its functions. These include: providing elasticity to the tissues, stabilizing the extracellular matrix, supporting or templating initial mineral deposition and binding other macromolecules. In different types of OI, mutations in the collagen genes are reflected in the inability of the OI bones to mineralize properly. Reviewed elsewhere, 28 the origin of the mineralization defect is unknown. This defect may be in the altered structure of the collagen itself, or in the inability of extracellular NCPs, which regulate the mineralization process, to bind to the defective collagen, and hence regulate mineralization.
Chemical analyses of the crosslinks in bone collagen have demonstrated two types of crosslinks, those formed enzymatically and those that occur by glycation. 33 ). In addition, the peak width of the BMDD (CaWidth) is distinctly enlarged, indicating an enormous heterogeneity in mineralization of the bone matrix. Examinations by histological staining techniques revealed a severe osteomalacia combined with signs of secondary hyperparathyroidism. Description of the individual BMDD indices derived from the BMDD curve: *CaMean, the weighted mean calcium concentration of the bone area obtained by the integrated area under the BMDD curve; *CaPeak, the peak position of the histogram, which indicates the most frequently occurring calcium concentration (mode calcium concentration); *CaWidth, the full-width at half-maximum of the distribution, describing the variation in mineralization density (heterogeneity); *CaLow, the percentage of bone area that is mineralized below the 5th percentile of the reference BMDD of normal adults, that is, below 17.68 weight percent calcium. This parameter corresponds normally to the amount of bone area undergoing primary mineralization. *CaHigh, the percentage of bone area that is mineralized above the 95th percentile of the reference BMDD of normal adults that is above 25. Bone composition and osteoporosis AL Boskey are altered in disease ( Table 2 ) and affect the mechanical strength of the collagenous matrix. Enzymatic crosslinks are believed to enhance mechanical strength, whereas the advanced glycosylation end-products, which are elevated in uncontrolled diabetics and in oxidative stress, make for a more brittle bone. Distribution of total crosslinks in the bone matrix can be visualized in FTIRI data ( Figure 5) . Such analyses agree with the high-performance liquid chromatography chemical analysis of crosslinks. 34 The number of these crosslinks, which reflect collagen maturity, is increased in osteoporotic individuals, especially in the center of the remaining cancellous bone. The heterogeneity of this distribution is decreased in consequence of age, osteoporosis and treatment with bisphosphonates. 35 
Bone composition and osteoporosis AL Boskey
Fibronectin. Fibronectin, a minor constituent of bone matrix, is one of the first proteins produced by osteoblasts, and directs the initial deposition of collagen fibrils. 36 Continued presence of fibronectin is also required to maintain the integrity of the collagenous matrix. 37 Studies with a variety of different conditional knockout animals demonstrated that while osteoblasts produce fibronectin, they are not responsible for the presence of the same in the bone extracellular matrix; rather, the bone matrix fibronectin is derived from circulating liver fibronectin. 38 In primary biliary cirrhosis, the incidence of osteoporosis is markedly elevated. This higher incidence is due to an increased production of a fibronectin isoform that lessens osteoblastic bone formation. 39 Noncollagenous proteins. There are several families of proteins that account for a small proportion of the extracellular matrix, which, as reviewed elsewhere, 40 serve important functions in matrix organization, cell signaling, metabolism and mineralization. Other than early studies showing a reduced NCP content of osteoporotic bone, 41 little has been written on how these proteins change in expression or distribution in osteoporosis or other bone diseases, with or without anabolic or antiresorptive therapies. Known changes in the expression of NCPs in health and disease are summarized in Table 3 . As shown in Table 3 , recent gene-wide association studies have identified several NCPs that may be related to fracture risk. In terms of actual measurement of protein content, findings to date are that osteocalcin and osteopontin are important for fracture resistance, 42 their concentrations are reduced in older osteonal bone 43 and osteopontin may retard crack propagation. 42 As a number of NCPs can and do interact with collagen fibrils, 40 they may function as 'glue', enhancing bone's resistance to fracture. 42 Recent studies have shown compositional differences between lamellae and interlamellar areas of cortical bone. The interlamellar areas have lower collagen content and increased concentration of NCPs. 44 The significance of such differences is as yet unknown. No published studies to date have examined changes in the expression of enzymes and signaling factors in the matrix of patients with metabolic bone disease.
Lipids. Less than 3% of the total bone matrix is fat soluble. Lipids are important for cell function, surrounding the cell body, regulating the flux of ions and signaling molecules into and out of the cell. The distribution of lipids in the matrix can be observed from histology, based on sudanophilia, from FTIR and Raman analysis or by nuclear magnetic resonance (NMR). 45 There are no recent published studies on lipid composition Bone composition and osteoporosis AL Boskey associated with fragility fractures or other bone diseases in humans. Thirty years ago, we did analyze the lipid composition of femoral heads from patients with avascular necrosis, reporting increased cholesterol content. 46 Water. The water content of bone may be demonstrated by proton NMR and can be assessed quantitatively by Raman spectroscopy 47 and gravimetric methods. 48 Water serves many functions, including filling the pores, interacting with collagen fibrils and binding to mineral crystals. 49 Unfortunately, the precise role of water in determining the mechanical competence of bone has not been determined. Analysis of water content shows a direct relationship between water and cortical porosity, which occurs with aging and osteoporosis (Figure 7) and is a key feature of renal osteodystrophy 50 and its associated osteoporosis. It is assumed, but not yet demonstrated, that decreases in porosity caused by bisphosphonate treatment will result in a lesser water content in both osteoporosis and renal osteodystrophy.
Composition Changes in Aging and Disease
Bone is a dynamic as well as a heterogeneous tissue; therefore, it is not surprising to see changes in composition as a function of age. 3 The types of compositional changes that have been reported are summarized in Table 4 . These are distinct from the changes discussed above that are associated with bone disease, fragility fractures or treatments to prevent such Bone composition and osteoporosis AL Boskey fractures. Important is the observation that some agedependent changes in composition are due to alterations in cell activity and protein expression as well as changes in the concentration and post-translational modification 40 of those NCPs that regulate matrix composition and mineralization. Therapies to limit the extent of bone disease are directed against these very same cells.
Compositional changes induced by therapies for osteoporosis. The interesting and important observation is that treatments for osteoporosis while decreasing fracture incidence do not consistently correct the above compositional abnormalities. Therapies currently used ( Table 5 ), other than supplements of calcium, vitamin D and phosphate, fall into two classes: anabolic agents and antiresorptive agents. These therapies all increase or maintain BMD. They each, however, have distinct effects on compositional properties and heterogeneity of their distribution. The most informative of the studies in Table 5 are those based on biopsies before and after treatment. Not every study examined the same tissue site, dose of drug or duration of treatment, and many did not compare the resulting data to the same tissue site in an untreated control. The few instances where this comparison was carried out, and the therapy returned the parameter in question to healthy control values are emphasized in Table 5 . Where no human data exists, animal data is included, with the caveat that this does not mean the same alterations will occur in man. Bisphosphonates, alendronate in particular, decreased the heterogeneity of the tissue, rather than increasing it, as would be appropriate for a mechanically strong tissue. Parathyroid hormone, an anabolic agent, and strontium ranelate both increase heterogeneity, determined by FTIRI, Raman and micro-CT measurements. Calcitriol's effect on bone composition has not been determined, neither were the effects of sclerostin antibodies. Odanatacib, the cathepsin K inhibitor, has been shown to affect composition based on BMDD measurements. Most of the antiresorptive therapies for osteoporosis (estrogen, bisphosphonates, calcitonin, cathepsin K inhibitors) increase mineral/matrix ratio, decrease crystallinity and return other FTIR and Raman parameters to less osteoporotic values without returning these values to normalcy. The anabolic agent PTH and strontium-ranelate, which may have both catabolic and anabolic properties, correct many of these FTIRI properties and increase tissue heterogeneity. Many of the therapies lead to retention of existing 'older' bone. Older bone has increased collagen maturity and increased crystal size. Anabolic agents, in contrast, stimulate new bone formation and the tissue acquired has characteristics of younger bone.
Loss of material heterogeneity, in fracture mechanics, is associated with an increase in brittleness, hence a greater risk of fracture. The importance of heterogeneity is seen in lumber structure and in development of stronger cements and plastics. Bisphosphonate treatment usually results in an increase of bone mineral density and bone volume, or in its maintenance. Bisphosphonate treatment is often accompanied by a decrease in heterogeneity. The reason for this event is as yet uncertain. It may be that there is a balance in these two opposing effects. The use of bisphosphonates results in an increase in BMD and bone volume, hence an increase in bone stiffness and strength. The use of bisphosphonates also causes a decrease in bone heterogeneity, which in turn increases bone brittleness. If this Bone composition and osteoporosis AL Boskey balance is disturbed, as in 'oversuppression' of bone turnover, failure may occur. Thus, the composition of bone in the healthy individual must be maintained and adjusted, similar to the structure described by Wolff's law, so as to optimize the function of bone.
Conclusions
This review of mineral and matrix properties in healthy and diseased bones demonstrates that these properties show both age-and disease-dependent changes. Bone disease and therapies for these diseases also affect the composition of bone. Bisphosphonates increase bone quantity but their effects on bone quality are variable. The effects of many other agents used in the treatment of osteoporosis are still under investigation. Some bisphosphonates decrease tissue heterogeneity, which may in turn increase brittleness. The origins of this effect and the significance of the alteration in bone quality remain to be determined.
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